mutation_id,virus,genotype,gene,aa_change,Ganciclovir,Cidofovir,Foscarnet,Brincidofovir,Letermovir,Tomeglovir,GW275175,Maribavir,Cyclopropavir,ref_review,ref_title,ref_link,ref_doi,test_method,tm_class,co_gene,co_aa,created_date,created_by,note,status
1,HCMV,TOWNE,UL54,D301N,2.6,3,0.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
2,HCMV,AD169,UL54,C304S,1.3,1.4,1.1,,,,,,,,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
3,HCMV,TOWNE,UL54,N408D,4.9,5.6,1.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
4,AD169,AD169,UL54,N408K,4.2,21,0.7,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.,https://europepmc.org/article/pmc/pmc1797699,DOI: 10.1128/AAC.00633-06,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
5,HCMV,AD169,UL54,N408S,3.1,7.5,1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model",https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub,https://doi.org/10.1016/j.antiviral.2013.02.002,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
6,HCMV,TOWNE,UL54,N410K,2.9,3,0.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
7,HCMV,TOWNE,UL54,F412C,4.2,18,1.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
8,HCMV,AD169,UL54,F412L,4.6,9.4,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
9,HCMV,AD169,UL54,F412S,5.3,13,0.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
10,HCMV,TOWNE,UL54,F412V,4.3,15.5,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
11,HCMV,AD169,UL54,D413A,6.5,11,0.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients,https://www.sciencedirect.com/science/article/pii/S1386653206004161,https://doi.org/10.1016/j.jcv.2006.11.005,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
12,HCMV,TOWNE,UL54,D413E,4.8,4.3,0.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
13,HCMV,AD169,UL54,D413N,3.8,10,1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/,doi: 10.1128/AAC.03214-14,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
14,HCMV,Susceptable Clinical Isolate,UL54,P488R,3.5,7.9,0.6,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
15,HCMV,,UL54,N495K,1.1,1.1,3.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet,Antiviral Therapy 2006;,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
16,HCMV,AD169,UL54,K500N,3.2,3,1.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,11: 537–540.,,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
17,HCMV,TOWNE,UL54,L501I,6,9.1,1.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
18,HCMV,TOWNE,UL54,T503I,2.9,6.1,0.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
19,HCMV,AD169,UL54,A505V,1.8,2,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Phenotypic Evaluation of Previously Uncharacterized Cytomegalovirus DNA Polymerase Sequence Variants Detected in a Valganciclovir Treatment Trial,https://academic.oup.com/jid/article/209/8/1219/831553,https://doi.org/10.1093/infdis/jit654,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,minor disparity in fold change ref - rev. ignoring Rev using original reference only,A
20,HCMV,TOWNE,UL54,K513E,5,9.1,1.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
21,HCMV,AD169,UL54,K513N,6,12.5,1.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture,https://www.sciencedirect.com/science/article/pii/S0042682298992996,https://doi.org/10.1006/viro.1998.9299,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
22,HCMV,AD169,UL54,K513N,9.8,34,3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture,https://www.sciencedirect.com/science/article/pii/S0042682298992996,https://doi.org/10.1006/viro.1998.9299,Marker Transfer - PRA,in vitro,UL54,V812L,17/11/2019,OJCharles,,A
23,HCMV,AD169,UL54,K513R,3.7,10,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/,doi: 10.1128/AAC.03214-14,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
24,HCMV,Clinical Isolate,UL54,D515E,2.7,,4.6,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"Drug-resistant human cytomegalovirus infection in children after allogeneic
stem cell transplantation may have different clinical outcomes",https://ashpublications.org/blood/article/96/9/3286/181219/Drug-resistant-human-cytomegalovirus-infection-in?searchresult=1,DOI: 10.1182/blood.V96.9.3286.h8003286_3286_3289,Lab derived mutant - PRA or SEAP,in vitro,UL54,L516M;I521T,17/11/2019,OJCharles,,A
25,HCMV,TOWNE,UL54,D515G,1,1,1.2,,,,,,,,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,Marker Transfer - PRA,in vitro,,,16/03/2020,OJCharles,,A
26,HCMV,Clinical Isolate,UL54,D515Y,6.2,0.9,4.7,,,,,,,,"Contrasting effect of new HCMV pUL54 mutations on antiviral drug
susceptibility: Benefits and limits of 3D analysis",https://www.sciencedirect.com/science/article/pii/S0166354216300365?via%3Dihub,https://doi.org/10.1016/j.antiviral.2016.02.004,Recombinant BAC - GFP fluorescence reduction assay,in vitro,,,23/11/2020,OJCharles,,A
27,HCMV,TOWNE,UL54,L516R,2.1,5.1,0.8,,,,,,,,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
28,HCMV,,UL54,I521T,2.1,5.1,0.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,Unable to substantiate review values from their references,U
29,HCMV,AD169,UL54,I521T,3,3.9,1,,,,,,,,Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus,http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf,doi:10.1016/j.jcv.2008.04.005.,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
30,HCMV,AD169,UL54,P522A,3,4.1,1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus,http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf,doi:10.1016/j.jcv.2008.04.005.,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
31,HCMV,AD169,UL54,P522L,1.3,1.2,1.4,,,,,,,,Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus,http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf,doi:10.1016/j.jcv.2008.04.005.,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
32,HCMV,TOWNE,UL54,P522S,3.1,3.6,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
33,HCMV,AD169,UL54,del524,3.5,9.7,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model",https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub,https://doi.org/10.1016/j.antiviral.2013.02.002,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
34,HCMV,AD169,UL54,V526L,5.5,2.5,1.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/,https://dx.doi.org/10.1128%2FJCM.02205-14,Recombinant BAC - GLuc reporter–based assay,in vitro,,,23/11/2020,OJCharles,,A
35,HCMV,AD169,UL54,C539G,3.1,4.4,1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/,doi: 10.1128/AAC.03214-14,,in vitro,,,17/11/2019,OJCharles,,A
36,HCMV,Susceptable Clinical Isolate,UL54,C539R,3.2,13.3,0.7,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
37,HCMV,,UL54,D542E,1.5,12,1.7,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Selection and Recombinant Phenotyping of a Novel CMX001 and Cidofovir Resistance Mutation in Human Cytomegalovirus,https://aac.asm.org/content/57/7/3321,DOI: 10.1128/AAC.00062-13,Recombinant BAC - PRA,in vitro,,,23/11/2020,OJCharles,,A
38,HCMV,AD169,UL54,V544A,1,1.1,0.9,,,,,,,,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
39,HCMV,TOWNE,UL54,L545S,3.5,9.1,1.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
40,HCMV,AD169,UL54,L545W,4.9,6.3,1.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
41,HCMV,AD169,UL54,T552N,1.9,1.2,2.6,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
42,HCMV,AD169,UL54,Q578H,3.3,2.3,4.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
43,HCMV,AD169,UL54,S585A,1.5,1.4,2.7,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
44,HCMV,TOWNE,UL54,D588E,1.3,1.1,2.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
45,HCMV,AD169,UL54,D588N,2,1.3,2.8,,,,,,,,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
46,HCMV,,UL54,D588N,3.8,2.7,9,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity,https://www.sciencedirect.com/science/article/pii/S1386653201001603?via%3Dihub,https://doi.org/10.1016/S1386-6532(01)00160-3,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
47,HCMV,Susceptable Clinical Isolate,UL54,F595I,1.3,1.2,2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
48,HCMV,TOWNE,UL54,A692S,1.6,1.7,3.3,,,,,,,,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,Marker Transfer - PRA,in vitro,,,16/03/2020,OJCharles,,A
49,HCMV,Clinical Isolate,UL54,T700A,1.2,1.3,5.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
50,HCMV,AD169,UL54,A714V,0.8,0.7,0.8,,,,,,,,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
51,HCMV,,UL54,V715M,1.3,1.1,9.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
52,HCMV,,UL54,V715M,1,1.1,5.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,,,17/11/2019,OJCharles,Unable to substantiate review values from their references,U
53,HCMV,AD169,UL54,I726V,1.9,1.9,1.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
54,HCMV,TOWNE,UL54,E756D,1.2,0.7,3.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
55,HCMV,AD169,UL54,E756K,8.1,2.7,8,,,,,,,,Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/,https://dx.doi.org/10.1128%2FJCM.02205-14,Recombinant BAC - GLuc reporter–based assay,in vitro,,,23/11/2020,OJCharles,,A
56,HCMV,TOWNE,UL54,E756Q,1.7,1,4.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Mutations Conferring Foscarnet Resistance in A Cohort of Patients with Acquired Immunodeficiency Syndrome and Cytomegalovirus Retinitis,https://academic.oup.com/jid/article/187/5/777/2191368,https://doi.org/10.1086/368385,Marker Transfer - PRA,in vitro,,,23/11/2020,OJCharles,,A
57,HCMV,AD169,UL54,L773V,3,2.5,4.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/,doi: 10.1128/AAC.03214-14,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
58,HCMV,AD169,UL54,L776M,2.5,1,3.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Artesunate as a Potent Antiviral Agent in a Patient with Late Drug-Resistant Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation,https://academic.oup.com/cid/article/46/9/1455/330370,https://doi.org/10.1086/587106,Marker Transfer - PRA,in vitro,,,23/11/2020,OJCharles,,A
59,HCMV,TOWNE,UL54,V781I,1,1.2,5.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
60,HCMV,,UL54,V787A,4.7,0.7,3.2,,,,,,,,"Contrasting effect of new HCMV pUL54 mutations on antiviral drug
susceptibility: Benefits and limits of 3D analysis",https://www.sciencedirect.com/science/article/pii/S0166354216300365?via%3Dihub,https://doi.org/10.1016/j.antiviral.2016.02.004,Recombinant BAC - GFP fluorescence reduction assay,in vitro,,,23/11/2020,OJCharles,,A
61,HCMV,TOWNE,UL54,V787L,2.4,1,4.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Mutations Conferring Foscarnet Resistance in A Cohort of Patients with Acquired Immunodeficiency Syndrome and Cytomegalovirus Retinitis,https://academic.oup.com/jid/article/187/5/777/2191368,https://doi.org/10.1086/368385,Marker Transfer - PRA,in vitro,,,23/11/2020,OJCharles,,A
62,HCMV,TOWNE,UL54,L802M,1.1,0.9,3.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
63,HCMV,AD169,UL54,L802V,1.8,1.1,0.9,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
64,HCMV,TOWNE,UL54,K805Q,1,2.2,0.18,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
65,HCMV,AD169,UL54,A809V,2.4,1.9,3.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Growth and Drug Resistance Phenotypes Resulting from Cytomegalovirus DNA Polymerase Region III Mutations Observed in Clinical Specimens,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151462/,https://dx.doi.org/10.1128%2FAAC.00736-07,Recombinant BAC - SEAP,in vitro,,,23/11/2020,OJCharles,,A
66,HCMV,AD169,UL54,A809V,,,3.6,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
67,HCMV,AD169,UL54,V812L,2.5,3.2,2.9,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,A  Point  Mutation  in  the  Human  Cytomegalovirus  DNA  Polymerase  Gene  Selectedin  Vitroby  Cidofovir  Confers  a  Slow  Replication  Phenotype  in  Cell  Culture,https://www.sciencedirect.com/science/article/pii/S0042682298992996?via%3Dihub,https://doi.org/10.1006/viro.1998.9299,Marker Transfer - PRA,in vitro,,,23/11/2020,OJCharles,,A
68,HCMV,AD169,UL54,T813S,2.5,2.7,4.9,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Growth and Drug Resistance Phenotypes Resulting from Cytomegalovirus DNA Polymerase Region III Mutations Observed in Clinical Specimens,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151462/,https://dx.doi.org/10.1128%2FAAC.00736-07,Recombinant BAC - SEAP,in vitro,,,23/11/2020,OJCharles,,A
69,HCMV,TOWNE,UL54,T821I,4.5,1.9,21,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
70,HCMV,AD169,UL54,P829S,2,1.6,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,https://dx.doi.org/10.1128%2FAAC.00334-11,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
71,HCMV,AD169,UL54,A834P,5.4,3,6.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.,https://europepmc.org/article/pmc/pmc1797699,DOI: 10.1128/AAC.00633-06,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
72,HCMV,AD169,UL54,A834P,22.7,18.8,7.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.,https://europepmc.org/article/pmc/pmc1797699,DOI: 10.1128/AAC.00633-06,Recombinant BAC - SEAP,in vitro,UL54,N408K,17/11/2019,OJCharles,,A
73,HCMV,TOWNE,UL54,T838A,1.8,0.8,2.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,How Evolution of Mutations Conferring Drug Resistance Affects Viral Dynamics and Clinical Outcomes of Cytomegalovirus-Infected Hematopoietic Cell Transplant Recipients,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC540138/,https://dx.doi.org/10.1128%2FJCM.43.1.208-213.2005,Marker Transfer - PRA,in vitro,,,23/11/2020,OJCharles,,A
74,HCMV,AD169,UL54,G841A,3.2,2.6,4.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Growth and Drug Resistance Phenotypes Resulting from Cytomegalovirus DNA Polymerase Region III Mutations Observed in Clinical Specimens,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151462/,https://dx.doi.org/10.1128%2FAAC.00736-07,Recombinant BAC - SEAP,in vitro,,,23/11/2020,OJCharles,,A
75,HCMV,AD169,UL54,M844T,1.4,1.3,2.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Cyclopropavir Susceptibility of Cytomegalovirus DNA Polymerase Mutants Selected after Antiviral Drug Exposure,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256009/,https://dx.doi.org/10.1128%2FAAC.05559-11,Lab derived mutant - PRA or SEAP,in vitro,,,23/11/2020,OJCharles,,A
76,HCMV,AD169,UL54,M844V,2.3,1.6,2.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Cyclopropavir Susceptibility of Cytomegalovirus DNA Polymerase Mutants Selected after Antiviral Drug Exposure,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256009/,https://dx.doi.org/10.1128%2FAAC.05559-11,Lab derived mutant - PRA or SEAP,in vitro,,,23/11/2020,OJCharles,,A
77,HCMV,Susceptable Clinical Isolate,UL54,L862F,1.7,0.9,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
78,HCMV,Susceptable Clinical Isolate,UL54,V946L,1.1,0.9,2.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
79,HCMV,AD169,UL54,L957F,2.7,1.4,1.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
80,HCMV,TOWNE,UL54,G971D,1.4,1,1.2,,,,,,,,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,Marker Transfer - PRA,in vitro,,,16/03/2020,OJCharles,,A
81,HCMV,TOWNE,UL54,del981-982,8.3,2.8,3.6,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,Marker Transfer - PRA,in vitro,,,23/11/2020,OJCharles,,A
82,HCMV,AD169,UL54,A987G,5.1,4.5,,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
83,HCMV,TOWNE,UL54,A987G,5.3,11.3,1.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
84,HCMV,Susceptable Clinical Isolate,UL54,L802M,1.7,1,2.7,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
85,HCMV,Susceptable Clinical Isolate,UL54,P488R,7.5,7.4,1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
86,HCMV,Susceptable Clinical Isolate,UL54,C539R,6.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,17/11/2019,OJCharles,,A
87,HCMV,Susceptable Clinical Isolate,UL54,C539R,59,7.4,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,UL97,H520Q,17/11/2019,OJCharles,,A
88,HCMV,Susceptable Clinical Isolate,UL54,C539R;F595I,28,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,UL97,G598D,17/11/2019,OJCharles,,A
89,HCMV,Susceptable Clinical Isolate,UL54,C539R; F595I,79,13,6.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,UL97,H520Q,17/11/2019,OJCharles,,A
90,HCMV,TOWNE,UL54,S676G,1.1,1.2,0.9,,,,,,,,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,16/03/2020,OJCharles,,A
91,HCMV,TOWNE,UL54,V759M,1.5,1.1,1.1,,,,,,,,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,,,16/03/2020,OJCharles,,A
92,HCMV,TOWNE,UL54,F412C,6.2,16,3.1,,,,,,,,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,UL54,L802M,16/03/2020,OJCharles,,A
93,HCMV,TOWNE,UL54,K513E,6.6,11.1,2.7,,,,,,,,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,UL54,D558E,16/03/2020,OJCharles,,A
94,HCMV,TOWNE,UL54,K805Q,4.3,2.1,10.1,,,,,,,,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,Marker Transfer - PRA,in vitro,UL54,T821I,16/03/2020,OJCharles,,A
95,HCMV,AD169,UL54,L545S,5,11.9,1,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
96,HCMV,AD169,UL54,D879G,1.2,0.9,0.9,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
97,HCMV,AD169,UL54,L545S,7.3,4.5,1.8,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,UL54,P829S,16/03/2020,OJCharles,,A
98,HCMV,AD169,UL54,N408D,4,4.2,1.3,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
99,HCMV,AD169,UL54,N408D,4.2,1.9,4,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,UL54,T552N,16/03/2020,OJCharles,,A
100,HCMV,AD169,UL54,N408D,4.9,4.5,3.3,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,UL54,L957F,16/03/2020,OJCharles,,A
101,HCMV,AD169,UL54,T552N,1.6,0.9,5.5,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,UL54,L957F,16/03/2020,OJCharles,,A
102,HCMV,AD169,UL54,N757K,1.3,0.8,1.3,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
103,HCMV,AD169,UL54,L802M,1.7,1,2.7,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
104,HCMV,AD169,UL54,L926V,1.3,1.1,0.9,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
105,HCMV,AD169,UL54,K500N,2.4,2.4,2.7,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,UL54,S585A,16/03/2020,OJCharles,,A
106,HCMV,Susceptable Clinical Isolate,UL54,V787L,1.8,0.9,2.4,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
107,HCMV,AD169,UL97,del590-593,4.8,1,,,,,,,,,New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/,,Lab derived mutant - PRA,in vitro,,,16/03/2020,OJCharles,,A
108,HCMV,AD169,UL54,L545S,7.4,16,1.5,,,,,,,,New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/,,Lab derived mutant - PRA,in vitro,,,16/03/2020,OJCharles,,A
109,HCMV,AD169,UL54,L545S,16,6.5,1.3,,,,,,,,New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/,,Lab derived mutant - PRA,in vitro,UL97,M460I,16/03/2020,OJCharles,,A
110,HCMV,AD169,UL54,T552N,3.2,2.1,5.8,,,,,,,,New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/,,Lab derived mutant - PRA,in vitro,,,16/03/2020,OJCharles,,A
111,HCMV,TOWNE,UL54,L737M,1.1,2,1,,,,,,,,Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.,https://europepmc.org/article/pmc/pmc1797699,DOI: 10.1128/AAC.00633-06,Marker Transfer - PRA,in vitro,,,16/03/2020,OJCharles,,A
112,HCMV,TOWNE,UL54,A834P,6.1,6,7.7,,,,,,,,Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.,https://europepmc.org/article/pmc/pmc1797699,DOI: 10.1128/AAC.00633-06,Marker Transfer - PRA,in vitro,,,16/03/2020,OJCharles,,A
113,HCMV,AD169,UL54,Q229K,1.2,1,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
114,HCMV,AD169,UL54,D247N,0.9,0.9,1.3,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
115,HCMV,AD169,UL54,D262N,1.1,1,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
116,HCMV,AD169,UL54,T271A,1,0.7,0.9,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
117,HCMV,AD169,UL54,V284E,1.2,1.1,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
118,HCMV,AD169,UL54,D288N,1.2,1.2,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
119,HCMV,AD169,UL54,F396L,1.4,0.9,0.9,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
120,HCMV,AD169,UL54,L424V,1.3,1.3,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
121,HCMV,AD169,UL54,T437M,1,1,0.8,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
122,HCMV,AD169,UL54,F460L,1.2,1.2,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
123,HCMV,AD169,UL54,A505V,1.9,1.9,1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
124,HCMV,AD169,UL54,A543S,1,1,1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
125,HCMV,AD169,UL54,S612N,0.9,1,0.7,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
126,HCMV,AD169,UL54,V654G,1.1,1.1,1.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
127,HCMV,AD169,UL54,S660G,1,0.9,1.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
128,HCMV,AD169,UL54,S660N,1.2,1,0.8,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
129,HCMV,AD169,UL54,G667N,0.9,0.8,1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
130,HCMV,AD169,UL54,A692G,0.8,0.9,1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
131,HCMV,AD169,UL54,I726T,2,1.7,1.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
132,HCMV,AD169,UL54,E793V,0.9,0.7,1.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
133,HCMV,AD169,UL54,Q795P,0.9,0.9,1.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
134,HCMV,AD169,UL54,Q795R,1,0.9,1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
135,HCMV,AD169,UL54,G841S,2.2,1.1,2.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
136,HCMV,AD169,UL54,P859A,0.8,1,0.8,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
137,HCMV,AD169,UL54,V902G,1.2,1,1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
138,HCMV,AD169,UL54,E903G,1.1,1,0.9,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
139,HCMV,AD169,UL54,K947E,1,1,1.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
140,HCMV,AD169,UL54,M959T,1.2,0.9,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
141,HCMV,AD169,UL54,N345S,1.2,0.7,0.9,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
142,HCMV,AD169,UL54,V467G,0.9,0.8,0.4,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
143,HCMV,AD169,UL54,Q578L,1.9,0.8,3,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,Recombinant BAC - PRA,in vitro,,,16/03/2020,OJCharles,,A
144,HCMV,,UL97,L595T,2-4,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,Mentioned in text  not in table mentioned. No original reference. typo?,U
145,HCMV,,UL97,D605E,Polymorphism,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Hypothesised,Anecdotal,,,17/11/2019,OJCharles,Typo?,U
146,HCMV,,UL97,F342S,7.8,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA,in vitro,,,17/11/2019,OJCharles,,A
147,HCMV,,UL97,del355,16,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
148,HCMV,,UL97,V356G,5.5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
149,HCMV,,UL97,L405P,2.5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/,10.1128/AAC.00186-10,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
150,HCMV,,UL97,D456N,12,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
151,HCMV,,UL97,M460I,5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
152,HCMV,,UL97,M460T,9.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/,10.1128/AAC.00186-10,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
153,HCMV,,UL97,M460V,8.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
154,HCMV,,UL97,V466G,3.5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
155,HCMV,,UL97,C480R,9,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
156,HCMV,,UL97,C518Y,12,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
157,HCMV,,UL97,H520Q,10,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
158,HCMV,,UL97,P521L,17,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
159,HCMV,,UL97,del591-594,6,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
160,HCMV,,UL97,del590-600,6.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
161,HCMV,,UL97,del590-603,,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
162,HCMV,,UL97,A591V,1.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
163,HCMV,,UL97,del591-607,6.2,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
164,HCMV,,UL97,C592F,31.5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
165,HCMV,AD169,UL97,C592G,3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/,10.1128/AAC.00186-10,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
166,HCMV,,UL97,A594E,3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
167,HCMV,,UL97,A594G,13.5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
168,HCMV,,UL97,A594P,2.9,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
169,HCMV,,UL97,A594T,2.7,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
170,HCMV,AD169,UL97,A594V,6.4,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/,https://dx.doi.org/10.1128%2FJCM.02205-14,Recombinant BAC - GLuc reporter–based assay,in vitro,,,23/11/2020,OJCharles,,A
171,HCMV,AD169,UL97,L595F,11.4,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/,https://dx.doi.org/10.1128%2FJCM.02205-14,Recombinant BAC - GLuc reporter–based assay,in vitro,,,23/11/2020,OJCharles,,A
172,HCMV,,UL97,L595S,9.2,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
173,HCMV,,UL97,L595W,5.1,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
174,HCMV,,UL97,del595,13.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
175,HCMV,,UL97,del595-603,8.4,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
176,HCMV,,UL97,del596,,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
177,HCMV,,UL97,E596G,2.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
178,HCMV,,UL97,E596Y,6.4,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
179,HCMV,,UL97,G598S,,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
180,HCMV,,UL97,K599E,,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
181,HCMV,,UL97,K599T,5.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
182,HCMV,,UL97,del600,1.9,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
183,HCMV,,UL97,del601-603,11,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
184,HCMV,,UL97,C603R,3.6-8.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
185,HCMV,,UL97,C603S,1.9,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
186,HCMV,,UL97,C603W,8,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
187,HCMV,,UL97,C607F,1.9,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
188,HCMV,,UL97,C607Y,12.5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
189,HCMV,,UL97,I610T,2.8,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
190,HCMV,,UL97,A613V,2.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
191,HCMV,,UL97,del617,10,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
192,HCMV,AD169,UL97,E655K,1.7,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/,https://dx.doi.org/10.1128%2FJCM.02205-14,Recombinant BAC - GLuc reporter–based assay,in vitro,,,23/11/2020,OJCharles,,A
193,HCMV,AD169,UL89,D344E,,,,,1.8,1.7,9.4,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-17,"https://doi.org/10
.1128/AAC.01325-17",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
194,HCMV,AD169,UL89,C347S,,,,,0.6,0.3,27,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-18,"https://doi.org/10
.1128/AAC.01325-18",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
195,HCMV,AD169,UL89,R351H,,,,,0.7,0.4,8.5,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-19,"https://doi.org/10
.1128/AAC.01325-19",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
196,HCMV,AD169,UL56,E769D,,,,,1,0.8,0.7,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-20,"https://doi.org/10
.1128/AAC.01325-20",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
197,HCMV,AD169,UL56,Q204R,,,,,1.5,2.7,4.2,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-21,"https://doi.org/10
.1128/AAC.01325-21",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
198,HCMV,AD169,UL56,Q204R,,,,,2.5,5.8,21,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-22,"https://doi.org/10
.1128/AAC.01325-22",Recombinant BAC - SEAP,in vitro,UL89,D344E,17/11/2019,OJCharles,,A
199,HCMV,AD169,UL56,N232Y,,,,,17,2.7,0.8,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-23,"https://doi.org/10
.1128/AAC.01325-23",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
200,HCMV,AD169,UL56,K258E,,,,,14,0.3,0.7,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-24,"https://doi.org/10
.1128/AAC.01325-24",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
201,HCMV,AD169,UL56,F261L,,,,,2.5,1,0.7,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-25,"https://doi.org/10
.1128/AAC.01325-25",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
202,HCMV,AD169,UL56,F261L,,,,,4.8,2.1,10,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-26,"https://doi.org/10
.1128/AAC.01325-26",Recombinant BAC - SEAP,in vitro,UL89,D344E,17/11/2019,OJCharles,,A
203,HCMV,AD169,UL56,M329T,,,,,4.5,1.1,0.8,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-27,"https://doi.org/10
.1128/AAC.01325-27",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
204,HCMV,AD169,UL56,M329T,,,,,8,2.2,10,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-28,"https://doi.org/10
.1128/AAC.01325-28",Recombinant BAC - SEAP,in vitro,UL89,D344E,17/11/2019,OJCharles,,A
205,HCMV,AD169,UL56,E237D,,,,,16,0.3,0.5,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-29,"https://doi.org/10
.1128/AAC.01325-29",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
206,HCMV,AD169,UL56,E237D,,,,,34,0.6,7.4,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-30,"https://doi.org/10
.1128/AAC.01325-30",Recombinant BAC - SEAP,in vitro,UL89,D344E,17/11/2019,OJCharles,,A
207,HCMV,AD169,UL89,N320H,,,,,1.8,6.5,4.2,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-31,"https://doi.org/10
.1128/AAC.01325-31",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
208,HCMV,AD169,UL89,M359I,,,,,1.5,7.4,0.5,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-32,"https://doi.org/10
.1128/AAC.01325-32",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
209,HCMV,AD169,UL89,I334V,,,,,1.1,0.9,0.9,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-33,"https://doi.org/10
.1128/AAC.01325-33",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
210,HCMV,AD169,UL89,N329S,,,,,2,15,0.7,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-34,"https://doi.org/10
.1128/AAC.01325-34",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
211,HCMV,AD169,UL89,T350M,,,,,2.8,8.7,5.1,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-35,"https://doi.org/10
.1128/AAC.01325-35",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
212,HCMV,AD169,UL89,V362M,,,,,1.2,98,0.6,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-36,"https://doi.org/10
.1128/AAC.01325-36",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
213,HCMV,AD169,UL89,H389N,,,,,1.1,29,0.9,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-37,"https://doi.org/10
.1128/AAC.01325-37",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
214,HCMV,AD169,UL89,N405D,,,,,1,15,0.7,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-38,"https://doi.org/10
.1128/AAC.01325-38",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
215,HCMV,AD169,UL89,I334V,,,,,1.2,12,0.6,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-39,"https://doi.org/10
.1128/AAC.01325-39",Recombinant BAC - SEAP,in vitro,UL89,N405D,17/11/2019,OJCharles,,A
216,HCMV,AD169,UL56,L208M,,,,,0.8,3.4,0.7,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-40,"https://doi.org/10
.1128/AAC.01325-40",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
217,HCMV,AD169,UL56,E407D,,,,,1.3,6,0.9,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-41,"https://doi.org/10
.1128/AAC.01325-41",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
218,HCMV,AD169,UL56,H637Q,,,,,0.9,2,0.9,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-42,"https://doi.org/10
.1128/AAC.01325-42",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
219,HCMV,AD169,UL56,V639M,,,,,1,10,0.9,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-43,"https://doi.org/10
.1128/AAC.01325-43",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
220,HCMV,AD169,UL56,H637Q,,,,,1.2,17,0.8,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-44,"https://doi.org/10
.1128/AAC.01325-44",Recombinant BAC - SEAP,in vitro,UL56,V639M,17/11/2019,OJCharles,,A
221,HCMV,AD169,UL56,L764M,,,,,1.1,0.4,1,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-45,"https://doi.org/10
.1128/AAC.01325-45",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
222,HCMV,AD169,UL54,del981-982,7.3,3.8,3.1,,,,,,,,"New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir",https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,"https://doi.org/10.1128/AAC
.00922-18",Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
223,HCMV,AD169,UL56,C25F,,,,,5.4,,,,,Antiviral Research 163 (2019) 91–105,"New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir",https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,"https://doi.org/10.1128/AAC
.00922-18",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
224,HCMV,AD169,UL56,L51M,,,,,0.8,,,,,,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
225,HCMV,AD169,UL56,S229F,,,,,1.8,,,,,Antiviral Research 163 (2019) 91–105,A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance,https://www.sciencedirect.com/science/article/pii/S0166354217306393,https://doi.org/10.1016/j.antiviral.2017.10.019,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
226,HCMV,AD169,UL56,V231A,,,,,2.1,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
227,HCMV,AD169,UL56,V231L,,,,,5.1,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
228,HCMV,,UL56,N232Y,,,,,17,,,,,Antiviral Research 163 (2019) 91–105,Chou (2017a),,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
229,HCMV,AD169,UL56,V236A,,,,,2.9,,,,,Antiviral Research 163 (2019) 91–105,"New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir",https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,"https://doi.org/10.1128/AAC
.00922-18",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
230,HCMV,AD169,UL56,V236L,,,,,14,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
231,HCMV,AD169,UL56,V236M,,,,,32,,,,,Antiviral Research 163 (2019) 91–105,A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance,https://www.sciencedirect.com/science/article/pii/S0166354217306393,https://doi.org/10.1016/j.antiviral.2017.10.019,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,Many ref & vals  this one seems representetive,A
232,HCMV,AD169,UL56,E237D,,,,,10,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
233,HCMV,AD169,UL56,L241P,,,,,96,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
234,HCMV,AD169,UL56,T244K,,,,,3.3,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
235,HCMV,,UL56,L254F,,,,,3.2,,,,,Antiviral Research 163 (2019) 91–105,Chou (2017b),,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
236,HCMV,,UL56,L257F,,,,,8.6,,,,,Antiviral Research 163 (2019) 91–105,,,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
237,HCMV,AD169,UL56,L257I,,,,,4.9,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
238,HCMV,,UL56,K258E,,,,,14,,,,,Antiviral Research 163 (2019) 91–105,,,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
239,HCMV,AD169,UL56,F261C,,,,,4.4,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
240,HCMV,AD169,UL56,F261L,,,,,2.8,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
241,HCMV,AD169,UL56,Y321C,,,,,4.6,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
242,HCMV,AD169,UL56,C325F,,,,,3000,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
243,HCMV,AD169,UL56,C325R,,,,,3000,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
244,HCMV,AD169,UL56,C325Y,,,,,3000,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
245,HCMV,,UL56,C325W,,,,,9000,,,,,Antiviral Research 163 (2019) 91–105,New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir,https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,https://doi.org/10.1128/AAC.00922-18,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
246,HCMV,,UL56,L328V,,,,,1.9,,,,,Antiviral Research 163 (2019) 91–105,,,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
247,HCMV,AD169,UL56,M329T,,,,,4.4,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
248,HCMV,AD169,UL56,A365S,,,,,2,,,,,Antiviral Research 163 (2019) 91–105,"New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir",https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,"https://doi.org/10.1128/AAC
.00922-18",Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
249,HCMV,,UL56,N368D,,,,,2,,,,,Antiviral Research 163 (2019) 91–105,,,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
250,HCMV,AD169,UL56,V231L,,,,,5,,,,,Antiviral Research 163 (2019) 91–105,Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure,https://aac.asm.org/content/aac/58/1/610.full.pdf,,Recombinant BAC - GFP fluorescence reduction assay,in vitro,,,17/11/2019,OJCharles,,A
251,HCMV,AD169,UL56,L241P,,,,,218,,,,,Antiviral Research 163 (2019) 91–105,Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure,https://aac.asm.org/content/aac/58/1/610.full.pdf,,Recombinant BAC - GFP fluorescence reduction assay,in vitro,,,17/11/2019,OJCharles,,A
252,HCMV,AD169,UL56,V236M,,,,,45,,,,,Antiviral Research 163 (2019) 91–105,Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure,https://aac.asm.org/content/aac/58/1/610.full.pdf,,Recombinant BAC - GFP fluorescence reduction assay,in vitro,,,17/11/2019,OJCharles,,A
253,HCMV,AD169,UL56,R369G,,,,,44,,,,,Antiviral Research 163 (2019) 91–105,Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure,https://aac.asm.org/content/aac/58/1/610.full.pdf,,Recombinant BAC - GFP fluorescence reduction assay,in vitro,,,17/11/2019,OJCharles,,A
254,HCMV,AD169,UL56,R369M,,,,,13,,,,,Antiviral Research 163 (2019) 91–105,Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure,https://aac.asm.org/content/aac/58/1/610.full.pdf,,Recombinant BAC - GFP fluorescence reduction assay,in vitro,,,17/11/2019,OJCharles,,A
255,HCMV,AD169,UL56,R369S,,,,,48,,,,,Antiviral Research 163 (2019) 91–105,Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure,https://aac.asm.org/content/aac/58/1/610.full.pdf,,Recombinant BAC - GFP fluorescence reduction assay,in vitro,,,17/11/2019,OJCharles,,A
256,HCMV,AD169,UL56,C25F,,,,,46,,,,,Antiviral Research 163 (2019) 91–105,"New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir",https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,"https://doi.org/10.1128/AAC
.00922-18",Recombinant BAC - SEAP,in vitro,UL56,V231L,17/11/2019,OJCharles,,A
257,HCMV,AD169,UL56,T244K,,,,,8.2,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,UL56,F261L,17/11/2019,OJCharles,,A
258,HCMV,AD169,UL56,E237D,,,,,104,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,UL56,T244K; F261L,17/11/2019,OJCharles,,A
259,HCMV,AD169,UL56,V236L,,,,,260,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,UL56,L257I,17/11/2019,OJCharles,,A
260,HCMV,AD169,UL56,V236M,,,,,3000,,,,,Antiviral Research 163 (2019) 91–105,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,Recombinant BAC - SEAP,in vitro,UL56,L257I; M329T,17/11/2019,OJCharles,,A
261,HCMV,AD169,UL56,S229F,,,,,54,,,,,Antiviral Research 163 (2019) 91–105,A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance,https://www.sciencedirect.com/science/article/pii/S0166354217306393,https://doi.org/10.1016/j.antiviral.2017.10.019,Recombinant BAC - SEAP,in vitro,UL56,L254F; L257I,17/11/2019,OJCharles,,A
262,HCMV,,UL89,N320H,,,,,1.8,,,,,Antiviral Research 163 (2019) 91–105,Chou (2017a),,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
263,HCMV,,UL89,N329S,,,,,2,,,,,Antiviral Research 163 (2019) 91–105,Chou (2017a),,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
264,HCMV,,UL89,D344E,,,,,1.7,,,,,Antiviral Research 163 (2019) 91–105,Chou (2017a),,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
265,HCMV,,UL89,T350M,,,,,2.8,,,,,Antiviral Research 163 (2019) 91–105,Chou (2017a),,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
266,HCMV,,UL56,E237D,,,,,34,,,,,Antiviral Research 163 (2019) 91–105,Chou (2017b),,,Recombinant BAC - SEAP,in vitro,UL89,D344E,17/11/2019,OJCharles,,A
267,HCMV,,UL56,F261L,,,,,4.8,,,,,Antiviral Research 163 (2019) 91–105,Chou (2017b),,,Recombinant BAC - SEAP,in vitro,UL89,D344E,17/11/2019,OJCharles,,A
268,HCMV,,UL56,M329T,,,,,8,,,,,Antiviral Research 163 (2019) 91–105,Chou (2017b),,,Recombinant BAC - SEAP,in vitro,UL89,D344E,17/11/2019,OJCharles,,A
269,HCMV,,UL56,Q204R,,,,,2.5,,,,,Antiviral Research 163 (2019) 91–105,Chou (2017b),,,Recombinant BAC - SEAP,in vitro,UL89,D344E,17/11/2019,OJCharles,,A
270,HCMV,,UL51,P91S,,,,,2.1,,,,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
271,HCMV,,UL51,P91S,,,,,6.3,,,,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,UL56,S229F,17/11/2019,OJCharles,,A
272,HCMV,,UL51,P91S,,,,,28,,,,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,UL56,V236M,17/11/2019,OJCharles,,A
273,HCMV,,UL51,P91S,,,,,126,,,,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,UL56,R369M,17/11/2019,OJCharles,,A
274,HCMV,,UL51,P91S,,,,,4,,,,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,UL89,D344E,17/11/2019,OJCharles,,A
275,HCMV,,UL97,L337M,1,,,,,,,3.4,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
276,HCMV,,UL97,F342S,7.8,17,,,,,,18,,Antiviral Research 163 (2019) 91–105,Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance,https://aac.asm.org/content/aac/57/7/3375.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
277,HCMV,,UL97,V353A,1,,,,,,,10,,Antiviral Research 163 (2019) 91–105,Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance,https://academic.oup.com/jid/article/196/1/91/844651,https://doi.org/10.1086/518514,Marker Transfer - PRA,in vitro,,,17/11/2019,OJCharles,,A
278,HCMV,AD169,UL97,del355,16,23,,,,,,304,,Antiviral Research 163 (2019) 91–105,Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance,https://aac.asm.org/content/aac/57/7/3375.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
279,HCMV,,UL97,V356G,5.5,7,,,,,,108,,Antiviral Research 163 (2019) 91–105,Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance,https://aac.asm.org/content/aac/57/7/3375.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
280,HCMV,,UL97,L397R,1.6,,,,,,,>200,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
281,HCMV,AD169,UL97,T409M,0.9,,,,,,,81,,Antiviral Research 163 (2019) 91–105,Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance,https://academic.oup.com/jid/article/196/1/91/844651,https://doi.org/10.1086/518514,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
282,HCMV,,UL97,H411L,0.7,,,,,,,69,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
283,HCMV,,UL97,H411N,1,,,,,,,9,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
284,HCMV,,UL97,H411Y,0.5,,,,,,,12,,Antiviral Research 163 (2019) 91–105,Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant,https://jvi.asm.org/content/82/1/246.short,DOI: 10.1128/JVI.01787-07,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
285,HCMV,,UL97,D456N,12,,,,,,,278,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
286,HCMV,,UL97,V466G,11,17,,,,,,321,,Antiviral Research 163 (2019) 91–105,Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance,https://aac.asm.org/content/aac/57/7/3375.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
287,HCMV,,UL97,C480R,9,,,,,,,243,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
288,HCMV,AD169,UL97,P521L,17,20,,,,,,445,,Antiviral Research 163 (2019) 91–105,Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance,https://aac.asm.org/content/aac/57/7/3375.full.pdf,,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
289,HCMV,,UL97,del617,10,,,,,,,372,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
290,HCMV,,UL97,V353A,1,,,,,,,227,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,UL97,H411L,17/11/2019,OJCharles,,A
291,HCMV,,UL97,V353A,0.7,,,,,,,164,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,UL97,H411Y,17/11/2019,OJCharles,,A
292,HCMV,,UL27,E22*,,,,,,,,2,,Antiviral Research 163 (2019) 91–105,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
293,HCMV,,UL27,W153R,,,,,,,,1.7,,Antiviral Research 163 (2019) 91–105,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
294,HCMV,,UL27,L193F,,,,,,,,2.6,,Antiviral Research 163 (2019) 91–105,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
295,HCMV,,UL27,del218,,,,,,,,2.5,,Antiviral Research 163 (2019) 91–105,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
296,HCMV,,UL27,R233S,,,,,,,,1.8-4.8,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
297,HCMV,,UL27,A269T,,,,,,,,2,,Antiviral Research 163 (2019) 91–105,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
298,HCMV,,UL27,del301-311,,,,,,,,3.1,,Antiviral Research 163 (2019) 91–105,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
299,HCMV,,UL27,L335P,,,,,,,,23,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
300,HCMV,,UL27,V353E,,,,,,,,2.1,,Antiviral Research 163 (2019) 91–105,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
301,HCMV,,UL27,W362R,,,,,,,,1.9,,Antiviral Research 163 (2019) 91–105,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,Recombinant BAC - SEAP,in vitro,,,17/11/2019,OJCharles,,A
302,HCMV,,UL27,W362*,,,,,,,,2.2,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
303,HCMV,,UL27,L426F,,,,,,,,2.2,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,,,17/11/2019,OJCharles,,A
304,HCMV,,UL27,A406V,,,,,,,,3.5,,Antiviral Research 163 (2019) 91–105,,,,Lab derived mutant - PRA or SEAP,in vitro,UL27,C415*,17/11/2019,OJCharles,,A
305,HCMV,,UL27,R233S,,,,,,,,7.2,,Antiviral Research 163 (2019) 91–105,,,,Recombinant BAC - SEAP,in vitro,UL97,S337M,17/11/2019,OJCharles,,A
306,HCMV,,UL27,R233S,,,,,,,,27,,Antiviral Research 163 (2019) 91–105,,,,Recombinant BAC - SEAP,in vitro,UL97,S337M,17/11/2019,OJCharles,,A
307,HCMV,,UL97,C670Y,Resistant,,,,,,,,,,Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches,https://www.tandfonline.com/doi/full/10.1080/09273948.2019.1645188,https://doi.org/10.1080/09273948.2019.1645188,Clinical Patient Observation,Anecdotal,,,19/11/2019,OJCharles,,A
308,HCMV,AD169,UL97,F342Y,6,,,,,,,4.5,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,Recombinant BAC - SEAP,in vitro,,,21/11/2019,OJCharles,,A
309,HCMV,AD169,UL97,C592G,3,,,,,,,,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
310,HCMV,AD169,UL97,H411Y,,,,,,,,18,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
311,HCMV,AD169,UL97,T409M,,,,,,,,90,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,Recombinant BAC - SEAP,in vitro,,,21/11/2019,OJCharles,,A
312,HCMV,AD169,UL97,K359E,3.8,,,,,,,1.2,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,Recombinant BAC - SEAP,in vitro,,,21/11/2019,OJCharles,,A
313,HCMV,AD169,UL97,K359Q,3.7,,,,,,,1.3,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,Recombinant BAC - SEAP,in vitro,,,21/11/2019,OJCharles,,A
314,HCMV,AD169,UL97,F342Y,5.9,,,,,,,56,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,Recombinant BAC - SEAP,in vitro,UL97,H411Y,21/11/2019,OJCharles,,A
315,HCMV,Clinical Isolate,UL54,S290R,Resistant,,Resistant,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
316,HCMV,Clinical Isolate,UL54,E303D,Resistant,Resistant,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
317,HCMV,Clinical Isolate,UL54,E303G,Resistant,Resistant,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
318,HCMV,Clinical Isolate,UL54,D413Y,Resistant,Resistant,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
319,HCMV,Clinical Isolate,UL54,K488R,Resistant,Resistant,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
320,HCMV,Clinical Isolate,UL54,E951D,Resistant,,Resistant,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
321,HCMV,Clinical Isolate,UL54,L516W,Resistant,Resistant,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
322,HCMV,Clinical Isolate,UL54,V715A,,,Resistant,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
323,HCMV,,UL97,A674T,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
324,HCMV,,UL97,L634Q,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
325,HCMV,,UL97,Y617H,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
326,HCMV,,UL97,M615V,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
327,HCMV,,UL97,D605E,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
328,HCMV,,UL97,T601M,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
329,HCMV,,UL97,L600I,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
330,HCMV,,UL97,K599E,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
331,HCMV,,UL97,K599R,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
332,HCMV,,UL97,N597D,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
333,HCMV,,UL97,E596D,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
334,HCMV,,UL97,A591V,2-5,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
335,HCMV,,UL97,del596,2-5,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
336,HCMV,,UL97,C603S,2-5,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
337,HCMV,,UL97,del596,2-5,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
338,HCMV,,UL97,del600-602,2-5,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
339,HCMV,,UL97,C607F,2-5,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
340,HCMV,,UL97,K355M,5-15,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
341,HCMV,,UL97,V466G,5-15,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,Lab derived mutant - PRA or SEAP,in vitro,,,21/11/2019,OJCharles,reference?,A
342,HCMV,Susceptable Clinical Isolate,UL97,A594V,Resistant,,,,,,,,,An overview of letermovir: a cytomegalovirus prophylactic option,Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.,https://www.ncbi.nlm.nih.gov/pubmed/14739146,DOI: 10.1093/jac/dkh065,Clinical Patient Observation,Anecdotal,,,16/03/2020,OJCharles,,U
343,HCMV,Susceptable Clinical Isolate,UL54,P522S,Resistant,Resistant,,,,,,,,An overview of letermovir: a cytomegalovirus prophylactic option,Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.,https://www.ncbi.nlm.nih.gov/pubmed/14739146,DOI: 10.1093/jac/dkh065,Clinical Patient Observation,Anecdotal,,,16/03/2020,OJCharles,,U
344,HCMV,AD169,UL56,V236M,1,1.9,1.1,,46,,,,,An overview of letermovir: a cytomegalovirus prophylactic option,Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir,https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract,. doi: 10.1093/infdis/jiv352,Recombinant BAC - GFP fluorescence reduction assay,in vitro,,,16/03/2020,OJCharles,,A
345,HCMV,AD169,UL56,D414N,0.4,0.3,0.4,,0.9,,,,,An overview of letermovir: a cytomegalovirus prophylactic option,Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir,https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract,. doi: 10.1093/infdis/jiv352,Recombinant BAC - GFP fluorescence reduction assay,in vitro,,,16/03/2020,OJCharles,,A
346,HCMV,AD169,UL56,S227I,0.4,0.3,0.4,,0.2,,,,,An overview of letermovir: a cytomegalovirus prophylactic option,Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir,https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract,. doi: 10.1093/infdis/jiv352,Recombinant BAC - GFP fluorescence reduction assay,in vitro,,,16/03/2020,OJCharles,,A
347,HCMV,AD169,UL56,R410G,0.8,0.2,0.4,,0.4,,,,,An overview of letermovir: a cytomegalovirus prophylactic option,Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir,https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract,. doi: 10.1093/infdis/jiv352,Recombinant BAC - GFP fluorescence reduction assay,in vitro,,,16/03/2020,OJCharles,,A
348,HCMV,,UL56,E237G,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,mentions a lot cant see,U
349,HCMV,,UL56,M31I,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
350,HCMV,,UL56,M31V,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
351,HCMV,,UL56,F41L,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
352,HCMV,,UL56,L26P,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
353,HCMV,,UL56,I48M,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
354,HCMV,,UL56,A103V,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
355,HCMV,,UL56,E141*,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
356,HCMV,,UL56,N148D,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
357,HCMV,,UL56,E157G,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
358,HCMV,,UL56,Q182K,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
359,HCMV,,UL56,Q213R,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
360,HCMV,,UL56,S255L,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
361,HCMV,,UL56,S269G,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
362,HCMV,,UL56,E276G,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
363,HCMV,,UL56,I313V,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
364,HCMV,,UL56,C325W,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
365,HCMV,,UL56,S378N,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
366,HCMV,,UL56,S445N,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
367,HCMV,,UL56,E485G,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
368,HCMV,,UL56,I535V,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
369,HCMV,,UL56,del542,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
370,HCMV,,UL56,Y575C,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
371,HCMV,,UL56,M641T,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
372,HCMV,,UL56,L658S,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
373,HCMV,,UL56,Y667H,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
374,HCMV,,UL56,S705F,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
375,HCMV,,UL56,V706A,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
376,HCMV,,UL56,L750P,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
377,HCMV,,UL56,Y757H,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
378,HCMV,,UL56,T775I,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
379,HCMV,,UL56,R816W,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
380,HCMV,,UL56,P846L,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
381,HCMV,,UL89,K41E,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
382,HCMV,,UL89,N74S,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
383,HCMV,,UL89,S102F,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
384,HCMV,,UL89,F124L,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
385,HCMV,,UL89,T132A,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
386,HCMV,,UL89,V146I,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
387,HCMV,,UL89,P176S,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
388,HCMV,,UL89,H243R,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
389,HCMV,,UL89,H246R,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
390,HCMV,,UL89,D309G,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
391,HCMV,,UL89,L323P,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
392,HCMV,,UL89,T331A,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
393,HCMV,,UL89,S373G,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
394,HCMV,,UL89,M406V,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
395,HCMV,,UL89,N426D,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
396,HCMV,,UL89,L458P,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
397,HCMV,,UL89,S521G,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
398,HCMV,,UL89,L522P,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
399,HCMV,,UL89,A532T,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
400,HCMV,,UL89,I572V,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
401,HCMV,,UL89,Q625*,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
402,HCMV,,UL89,T637A,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
403,HCMV,,UL89,V656A,,,,,Resistant,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
404,HCMV,AD169,UL54,V787A,2.9,1.3,5.25,,,,,,,,Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis,https://academic.oup.com/jid/article/220/8/1302/5519111,https://doi.org/10.1093/infdis/jiz298,Recombinant BAC - GLuc reporter–based assay,in vitro,,,16/03/2020,OJCharles,,A
405,HCMV,AD169,UL54,V787E,8.5,2.9,3.4,,,,,,,,Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis,https://academic.oup.com/jid/article/220/8/1302/5519111,https://doi.org/10.1093/infdis/jiz298,Recombinant BAC - GLuc reporter–based assay,in vitro,,,21/11/2019,OJCharles,,A
406,HCMV,AD169,UL54,V787K,3.2,1.8,9.4,,,,,,,,Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis,https://academic.oup.com/jid/article/220/8/1302/5519111,https://doi.org/10.1093/infdis/jiz298,Recombinant BAC - GLuc reporter–based assay,in vitro,,,21/11/2019,OJCharles,,A
407,HCMV,,UL54,L501F,,Resistant,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
408,HCMV,,UL54,A505T,,Resistant,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
409,HCMV,,UL97,H469Y,Resistant,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
410,HCMV,,UL97,A590V ,Resistant,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
411,HCMV,,UL54,D1129N,Resistant,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
412,HCMV,,UL54,V321I ,Resistant,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
413,HCMV,,UL97,L609F ,Resistant,Resistant,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
414,HCMV,,UL54,R1030C ,Resistant,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
415,HCMV,,UL54,G1031A,Resistant,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
416,HCMV,,UL54,L394F ,Resistant,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
417,HCMV,,UL54,E877K,Resistant,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
418,HCMV,,UL97,L609F,Resistant,Resistant,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
419,HCMV,,UL54,T892A,Resistant,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Clinical Patient Observation,Anecdotal,,,21/11/2019,OJCharles,,A
420,HCMV,,UL97,M460I,7.8,,,,,,,,12,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,Recombinant BAC - SEAP,in vitro,,,22/11/2019,OJCharles,,A
421,HCMV,,UL97,M460T,9.3,,,,,,,,10,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,Recombinant BAC - SEAP,in vitro,,,22/11/2019,OJCharles,,A
422,HCMV,,UL97,M460V,8.3,,,,,,,,4,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,Recombinant BAC - SEAP,in vitro,,,22/11/2019,OJCharles,,A
423,HCMV,,UL97,H520Q,7.8,,,,,,,,20,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,Recombinant BAC - SEAP,in vitro,,,22/11/2019,OJCharles,,A
424,HCMV,,UL97,C592G,3,,,,,,,,3.3,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,Recombinant BAC - SEAP,in vitro,,,22/11/2019,OJCharles,,A
425,HCMV,,UL97,A594V,8.6,,,,,,,,4.5,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,Recombinant BAC - SEAP,in vitro,,,22/11/2019,OJCharles,,A
426,HCMV,,UL97,L595S,8.5,,,,,,,,1.3,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,Recombinant BAC - SEAP,in vitro,,,22/11/2019,OJCharles,,A
427,HCMV,,UL97,C603R,8.3,,,,,,,,8.4,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,Recombinant BAC - SEAP,in vitro,,,22/11/2019,OJCharles,,A
428,HCMV,,UL97,C603S,1.9,,,,,,,,2.8,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,Recombinant BAC - SEAP,in vitro,,,22/11/2019,OJCharles,,A
429,HCMV,,UL97,C603W,7.9,,,,,,,,4.6,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,Recombinant BAC - SEAP,in vitro,,,22/11/2019,OJCharles,,A
430,HCMV,AD169,UL54,D515Y,3.2,2.6,,,,,,,,,Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection,https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135,https://doi.org/10.1111/ajt.15135,Recombinant BAC - SEAP,in vitro,,,22/11/2019,OJCharles,,A
431,HCMV,AD169,UL54,L516P,4.4,5.9,,,,,,,,,Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection,https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135,https://doi.org/10.1111/ajt.15135,Recombinant BAC - SEAP,in vitro,,,22/11/2019,OJCharles,,A
432,HCMV,AD169,UL54,del981-982,7,3.2,2.7,,,,,,,,Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection,https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135,https://doi.org/10.1111/ajt.15135,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
433,HCMV,,UL54,L415N,,,Resistant,,,,,,,,Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial,https://academic.oup.com/cid/article/68/4/632/5049442,https://doi.org/10.1093/cid/ciy549,Clinical Patient Observation,Anecdotal,,,22/11/2019,OJCharles,,A
434,HCMV,,UL54,S734P,,,Resistant,,,,,,,,Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial,https://academic.oup.com/cid/article/68/4/632/5049442,https://doi.org/10.1093/cid/ciy549,Clinical Patient Observation,Anecdotal,,,22/11/2019,OJCharles,,A
435,HCMV,AD169,UL54,A543P,4.7,16,0.6,,,,,,,,"New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir",https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,"https://doi.org/10.1128/AAC
.00922-18",Recombinant BAC - SEAP,in vitro,,,22/11/2019,OJCharles,,A
436,HCMV,AD169,UL54,S290R,1.7,1.4,2.3,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
437,HCMV,AD169,UL54,K426E,1.1,1,1.1,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
438,HCMV,AD169,UL54,N495K,1.3,1,2.6,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
439,HCMV,AD169,UL54,N495K,1.7,1.2,3.5,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,Recombinant BAC - SEAP,in vitro,UL54,Q738R,16/03/2020,OJCharles,,A
440,HCMV,AD169,UL54,T552N,1.8,1,2.5,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
441,HCMV,AD169,UL54,Q783R,1.8,0.9,1.7,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
442,HCMV,AD169,UL54,V798A,1.5,1.1,1.7,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
443,HCMV,AD169,UL54,E951D,1.8,1.2,3.9,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
444,HCMV,TOWNE,UL54,T419M,1,,8,,,,,,,,Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase,https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub,https://doi.org/10.1016/S1386-6532(02)00046-X,Drug induced lab mutant - CMV antigen ELISA ,in vitro,,,16/03/2020,OJCharles,,A
445,HCMV,TOWNE,UL54,Q578H,2,,10,,,,,,,,Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase,https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub,https://doi.org/10.1016/S1386-6532(02)00046-X,Drug induced lab mutant - CMV antigen ELISA ,in vitro,,,16/03/2020,OJCharles,,A
446,HCMV,TOWNE,UL54,L773V,2,,5,,,,,,,,Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase,https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub,https://doi.org/10.1016/S1386-6532(02)00046-X,Drug induced lab mutant - CMV antigen ELISA ,in vitro,,,16/03/2020,OJCharles,,A
447,HCMV,TOWNE,UL97,M460V,10,,1,,,,,,,,Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase,https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub,https://doi.org/10.1016/S1386-6532(02)00046-X,Drug induced lab mutant - CMV antigen ELISA ,in vitro,,,16/03/2020,OJCharles,,A
448,HCMV,,UL97,T419M,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Lab derived mutant - PRA or SEAP,in vitro,,,22/11/2019,OJCharles,not sure I trust this,U
449,HCMV,,UL97,N68D,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Lab derived mutant - PRA or SEAP,in vitro,,,16/03/2020,OJCharles,,A
450,HCMV,,UL97,L126Q,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Lab derived mutant - PRA or SEAP,in vitro,,,16/03/2020,OJCharles,,A
451,HCMV,,UL97,I244V,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Lab derived mutant - PRA or SEAP,in vitro,,,16/03/2020,OJCharles,,A
452,HCMV,AD169,UL97,D329H,Polymorphism,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir,https://academic.oup.com/jid/article/185/2/162/2191141,https://doi.org/10.1086/338362,Lab derived mutant - PRA,in vitro,,,16/03/2020,OJCharles,,A
453,HCMV,AD169,UL97,A427V,1.0,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome,https://academic.oup.com/jid/article/194/5/579/2191670,https://doi.org/10.1086/505882,Lab derived mutant - PRA,in vitro,,,16/03/2020,OJCharles,,A
454,HCMV,,UL97,Q449K,Polymorphism,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance,https://academic.oup.com/jid/article-lookup/doi/10.1086/518514,https://doi.org/10.1086/518514,Lab derived mutant - SEAP,in vitro,,,16/03/2020,OJCharles,,A
455,HCMV,AD169,UL97,V466M,1.3,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/,10.1128/AAC.00186-10,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
456,HCMV,AD169,UL97,H469Y,1.2,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/,10.1128/AAC.00186-10,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
457,HCMV,AD169,UL97,A478V,0.8,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/,10.1128/AAC.00186-10,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
458,HCMV,AD169,UL97,N510S,1.2,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/,10.1128/AAC.00186-10,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
459,HCMV,AD169,UL97,M550I,0.85,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome,https://academic.oup.com/jid/article/194/5/579/2191670,https://doi.org/10.1086/505882,Lab derived mutant - PRA,in vitro,,,16/03/2020,OJCharles,,A
460,HCMV,AD169,UL97,A582V,0.82,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome,https://academic.oup.com/jid/article/194/5/579/2191670,https://doi.org/10.1086/505882,Lab derived mutant - PRA,in vitro,,,16/03/2020,OJCharles,,A
461,HCMV,AD169,UL97,H587Y,1.0,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/,10.1128/AAC.49.7.2710-2715.2005,Lab derived mutant - SEAP,in vitro,,,16/03/2020,OJCharles,,A
462,HCMV,AD169,UL97,A588V,1.1,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/,10.1128/AAC.00186-10,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
463,HCMV,,UL97,A591V,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Lab derived mutant - PRA or SEAP,in vitro,,,16/03/2020,OJCharles,unable to find referred mutation,U
464,HCMV,AD169,UL97,N597D,1.4,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786239/,doi:10.1002/jmv.21397,Lab derived mutant - SEAP,in vitro,,,16/03/2020,OJCharles,,A
465,HCMV,AD169,UL97,K599R,0.9,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/,10.1128/AAC.00186-10,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
466,HCMV,AD169,UL97,L600I,1.4,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/,10.1128/AAC.00186-10,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
467,HCMV,,UL97,D605E,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Lab derived mutant - PRA or SEAP,in vitro,,,16/03/2020,OJCharles,,A
468,HCMV,,UL97,M615V,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Lab derived mutant - PRA or SEAP,in vitro,,,16/03/2020,OJCharles,,A
469,HCMV,AD169,UL97,Y617H,0.84,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome,https://academic.oup.com/jid/article/194/5/579/2191670,https://doi.org/10.1086/505882,Lab derived mutant - PRA,in vitro,,,16/03/2020,OJCharles,,A
470,HCMV,AD169,UL97,G623S,1.1,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/,10.1128/AAC.00186-10,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
471,HCMV,,UL97,L634Q,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Lab derived mutant - PRA or SEAP,in vitro,,,16/03/2020,OJCharles,,A
472,HCMV,AD169,UL97,T659I,1.2,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/,10.1128/AAC.00186-10,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
473,HCMV,,UL97,V665I,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Lab derived mutant - PRA or SEAP,in vitro,,,16/03/2020,OJCharles,,A
474,HCMV,AD169,UL97,A674T,0.92,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome,https://academic.oup.com/jid/article/194/5/579/2191670,https://doi.org/10.1086/505882,Lab derived mutant - PRA,in vitro,,,16/03/2020,OJCharles,,A
475,HCMV,Clinical Isolate,UL97,Q19E,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
476,HCMV,Clinical Isolate,UL97,T95S,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
477,HCMV,Clinical Isolate,UL97,S108N,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
478,HCMV,Clinical Isolate,UL97,R112C,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
479,HCMV,Clinical Isolate,UL97,R137C,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
480,HCMV,Clinical Isolate,UL97,E227D,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
481,HCMV,Clinical Isolate,UL97,A582T,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
482,HCMV,,UL54,D515G,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Lab derived mutant - PRA or SEAP,in vitro,,,16/03/2020,OJCharles,,A
483,HCMV,,UL54,P522L,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Lab derived mutant - PRA or SEAP,in vitro,,,16/03/2020,OJCharles,,A
484,HCMV,,UL54,A692S,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Lab derived mutant - PRA or SEAP,in vitro,,,16/03/2020,OJCharles,,A
485,HCMV,,UL54,G971D,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Lab derived mutant - PRA or SEAP,in vitro,,,16/03/2020,OJCharles,,A
486,HCMV,Clinical Isolate,UL54,A15T,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
487,HCMV,Clinical Isolate,UL54,S24L,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
488,HCMV,Clinical Isolate,UL54,S32P,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
489,HCMV,Clinical Isolate,UL54,V95E,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
490,HCMV,Clinical Isolate,UL54,H142Y,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
491,HCMV,Clinical Isolate,UL54,G143S,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
492,HCMV,Clinical Isolate,UL54,I341T,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
493,HCMV,Clinical Isolate,UL54,N345S,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
494,HCMV,Clinical Isolate,UL54,G347D,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
495,HCMV,Clinical Isolate,UL54,V355A,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
496,HCMV,Clinical Isolate,UL54,S464F,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
497,HCMV,Clinical Isolate,UL54,A626V,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
498,HCMV,Clinical Isolate,UL54,P628L,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
499,HCMV,Clinical Isolate,UL54,G629S,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
500,HCMV,Clinical Isolate,UL54,A631G,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
501,HCMV,Clinical Isolate,UL54,S633F,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
502,HCMV,Clinical Isolate,UL54,M640R,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
503,HCMV,Clinical Isolate,UL54,S655L,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
504,HCMV,Clinical Isolate,UL54,S663N,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
505,HCMV,Clinical Isolate,UL54,F669L,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
506,HCMV,Clinical Isolate,UL54,S676G,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
507,HCMV,Clinical Isolate,UL54,G678S,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
508,HCMV,Clinical Isolate,UL54,del 681-688,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
509,HCMV,Clinical Isolate,UL54,N685S,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
510,HCMV,Clinical Isolate,UL54,A688V,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
511,HCMV,Clinical Isolate,UL54,T691A,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
512,HCMV,Clinical Isolate,UL54,A693T,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
513,HCMV,Clinical Isolate,UL54,S695T,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
514,HCMV,Clinical Isolate,UL54,Q697H,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
515,HCMV,Clinical Isolate,UL54,L737M,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
516,HCMV,Clinical Isolate,UL54,V759M,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
517,HCMV,Clinical Isolate,UL54,Q868R,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
518,HCMV,Clinical Isolate,UL54,D870H,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
519,HCMV,Clinical Isolate,UL54,V873L,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
520,HCMV,Clinical Isolate,UL54,G874R,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
521,HCMV,Clinical Isolate,UL54,S884Insert T,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
522,HCMV,Clinical Isolate,UL54,A885S,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
523,HCMV,Clinical Isolate,UL54,A885T,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
524,HCMV,Clinical Isolate,UL54,P887S,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
525,HCMV,Clinical Isolate,UL54,L890F,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
526,HCMV,Clinical Isolate,UL54,T892I,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
527,HCMV,Clinical Isolate,UL54,S897L,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
528,HCMV,Clinical Isolate,UL54,N898D,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
529,HCMV,Clinical Isolate,UL54,E899K,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
530,HCMV,Clinical Isolate,UL54,V927M,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
531,HCMV,Clinical Isolate,UL54,V953A,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
532,HCMV,Clinical Isolate,UL54,A1012V,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
533,HCMV,Clinical Isolate,UL54,L1020I,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
534,HCMV,Clinical Isolate,UL54,T1108A,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
535,HCMV,Clinical Isolate,UL54,N1116H,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
536,HCMV,Clinical Isolate,UL54,A1122T,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
537,HCMV,Clinical Isolate,UL54,G1133S,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
538,HCMV,Clinical Isolate,UL54,S1146N,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
539,HCMV,Clinical Isolate,UL54,N1147S,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
540,HCMV,Clinical Isolate,UL54,R1149T,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
541,HCMV,Clinical Isolate,UL54,del1151,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
542,HCMV,Clinical Isolate,UL54,P1153S,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
543,HCMV,Clinical Isolate,UL54,A1154P,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
544,HCMV,Clinical Isolate,UL54,del1156,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
545,HCMV,Clinical Isolate,UL54,P1162L,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
546,HCMV,Clinical Isolate,UL54,S1235T,Polymorphism,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Observed in baseline sequences or drug-sensetive clinical isolates,Anecdotal,,,16/03/2020,OJCharles,,A
547,HCMV,Clinical Isolate,UL97,C603W,1.1,0.9,1.5,,,,,,,,High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes,https://academic.oup.com/jid/article/176/1/69/901024,https://doi.org/10.1086/514041,Marker Transfer - PRA,in vitro,,,16/03/2020,OJCharles,,A
548,HCMV,Clinical Isolate,UL97,H469Y,1.3,1.5,1.9,,,,,,,,High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes,https://academic.oup.com/jid/article/176/1/69/901024,https://doi.org/10.1086/514041,Marker Transfer - PRA,in vitro,,,16/03/2020,OJCharles,,A
549,HCMV,Clinical Isolate,UL97,C603W,2,0.8,2,,,,,,,,High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes,https://academic.oup.com/jid/article/176/1/69/901024,https://doi.org/10.1086/514041,Marker Transfer - PRA,in vitro,,,16/03/2020,OJCharles,,A
550,HCMV,AD169,UL54,del413,3.8,5.8,1.3,5.2,,,,,,,Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/,10.1128/AAC.00214-16,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
551,HCMV,AD169,UL54,A809V,,,4.3,,,,,,,,Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/,10.1128/AAC.00214-16,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
552,HCMV,AD169,UL54,E303G,7.3,20,0.8,11,,,,,,,Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/,10.1128/AAC.00214-16,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
553,HCMV,AD169,UL54,E303D,6.3,16,0.8,9.7,,,,,,,Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/,10.1128/AAC.00214-16,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
554,HCMV,AD169,UL54,N408K,3.9,21,0.8,11,,,,,,,Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/,10.1128/AAC.00214-16,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
555,HCMV,AD169,UL54,D413Y,4.4,9.3,1,6,,,,,,,Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/,10.1128/AAC.00214-16,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
556,HCMV,AD169,UL54,V812L,2.1,3.1,2,2.4,,,,,,,Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/,10.1128/AAC.00214-16,Recombinant BAC - SEAP,in vitro,,,16/03/2020,OJCharles,,A
557,HCMV,AD169,UL54,E303G,10,34,1.4,17,,,,,,,Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/,10.1128/AAC.00214-16,Recombinant BAC - SEAP,in vitro,UL54,V812L,16/03/2020,OJCharles,,A
558,HCMV,AD169,UL56,M3V,,,,,1.0 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
559,HCMV,AD169,UL56,V236M,,,,,50.2 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
560,HCMV,AD169,UL56,E237G,2.1 ,1.4 ,1.3 ,,13.0 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
561,HCMV,AD169,UL56,S255L,,,,,1.1 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
562,HCMV,AD169,UL56,C325W,1.2 ,1 ,1.1 ,,8262.0 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
563,HCMV,AD169,UL56,R369T,1.5 ,1.2 ,1.1 ,,52.0 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
564,HCMV,AD169,UL56,del445-447,,,,,1.0 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,UL56,E485G,14/05/2020,OJCharles,,A
565,HCMV,AD169,UL56,E485G,,,,,0.9 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
566,HCMV,AD169,UL56,Y575C,,,,,0.9 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
567,HCMV,AD169,UL56,F626S,,,,,0.5 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
568,HCMV,AD169,UL56,L726V,,,,,1.0 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
569,HCMV,AD169,UL56,T775I,,,,,1.0 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
570,HCMV,AD169,UL56,del789-791,,,,,1.0 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
571,HCMV,AD169,UL56,V814A,,,,,1.0 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
572,HCMV,AD169,UL56,R816W,,,,,0.9 ,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
573,HCMV,AD169,UL89,I531T,,,,,1.0,,,,,,Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients,https://academic.oup.com/jid/article/221/7/1117/5645458,https://doi.org/10.1093/infdis/jiz577,Recombinant BAC - SEAP,in vitro,,,14/05/2020,OJCharles,,A
574,HCMV,AD169,UL54,Q579I,0.16,,0.06,,,,,,,,"Hypersusceptibility of Human Cytomegalovirus to Foscarnet
Induced by Mutations in Helices K and P of the Viral DNA
Polymerase",https://aac.asm.org/content/aac/64/4/e01910-19.full.pdf,https://doi.org/10.1128/AAC.01910-19,Recombinant BAC - GLuc reporter–based assay,in vitro,,,22/07/2020,OJCharles,,A
575,HCMV,AD169,UL54,K805Q,1.0,,0.19,,,,,,,,"Hypersusceptibility of Human Cytomegalovirus to Foscarnet
Induced by Mutations in Helices K and P of the Viral DNA
Polymerase",https://aac.asm.org/content/aac/64/4/e01910-19.full.pdf,https://doi.org/10.1128/AAC.01910-19,Recombinant BAC - GLuc reporter–based assay,in vitro,,,22/07/2020,OJCharles,,A
576,HCMV,AD169,UL54,E756K,12.7,2.9,5.3,,,,,,,,Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/,https://dx.doi.org/10.1128%2FJCM.02205-14,Recombinant BAC - GLuc reporter–based assay,in vitro,UL54,A594V,23/11/2020,OJCharles,,A
577,HCMV,AD169,UL54,V526L,13.2,2.7,1.7,,,,,,,,Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/,https://dx.doi.org/10.1128%2FJCM.02205-14,Recombinant BAC - GLuc reporter–based assay,in vitro,UL54,A594V,23/11/2020,OJCharles,,A
578,HCMV,AD169,UL54,V526L,18.9,3.5,1.9,,,,,,,,Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/,https://dx.doi.org/10.1128%2FJCM.02205-14,Recombinant BAC - GLuc reporter–based assay,in vitro,UL54,L595F,23/11/2020,OJCharles,,A
579,HCMV,AD169,UL54,P744T,0.9,1.1,1.1,,,,,,,,Cyclopropavir Susceptibility of Cytomegalovirus DNA Polymerase Mutants Selected after Antiviral Drug Exposure,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256009/,https://dx.doi.org/10.1128%2FAAC.05559-11,Lab derived mutant - PRA or SEAP,in vitro,,,23/11/2020,OJCharles,,A
